| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | ANAGENICS LIMITED: Appendix 4C & Activity Report for Q4 FY2026 | - | ASX | ||
| 27.07. | ANAGENICS LIMITED: Change of Auditor | - | ASX | ||
| 27.04. | ANAGENICS LIMITED: AN1 - Appendix 4C & Activity Report for Q3 FY2026 | - | ASX | ||
| 17.04. | ANAGENICS LIMITED: Notification of cessation of securities - AN1 | - | ASX | ||
| 02.03. | ANAGENICS LIMITED: Appendix 3X MR JOSHUA GORDON | - | ASX | ||
| 02.03. | ANAGENICS LIMITED: AN1 - Director Appointment | - | ASX | ||
| 27.02. | ANAGENICS LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
| ANAGENICS Aktie jetzt für 0€ handeln | |||||
| 25.02. | ANAGENICS LIMITED: AN1 - 1H FY26 Presentation | 1 | ASX | ||
| 24.02. | ANAGENICS LIMITED: Anagenics - 1H FY26 Result Highlights | - | ASX | ||
| 24.02. | ANAGENICS LIMITED: Anagenics - 1H26 HY Report DEC 2025 | - | ASX | ||
| 24.02. | ANAGENICS LIMITED: Appendix 4D 1H FY26 DEC 2025 | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Becoming a substantial holder | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Becoming a substantial holder | - | ASX | ||
| 12.02. | ANAGENICS LIMITED: Notification regarding unquoted securities - AN1 | 1 | ASX | ||
| 09.02. | ANAGENICS LIMITED: Ceasing to be a substantial holder from FOS | 1 | ASX | ||
| 09.02. | ANAGENICS LIMITED: Change in substantial holding from HNG | 1 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 40,970 | -0,06 % | Novo Nordisk, Johnson & Johnson und Co. setzen auf Plattformen - warum einzelne Medikamente für Big Pharma längst nicht mehr ausreichen | ||
| AURORA CANNABIS | 2,598 | +0,93 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Fiscal 2027 First Quarter Results | NASDAQ | TSX: ACB
Delivers Net Revenue of $67.6 million, including a 17% YoY Increase in International Medical Cannabis Net Revenue
Safari Flower Company Receives Three-Year EU-GMP... ► Artikel lesen | |
| CANOPY GROWTH | 0,841 | -0,10 % | Canopy Growth übertrifft Gewinnerwartungen für Q1 2027 - Aktie legt zu | ||
| TILRAY BRANDS | 3,955 | +0,13 % | Tilray-Aktie: Startet jetzt die 700%-Chance? | Die Tilray-Aktie hat in den vergangenen Tagen eine bemerkenswerte Kehrtwende vollzogen. Nach enttäuschenden Quartalszahlen am 28. Juli geriet der Cannabis-Titel zunächst unter Druck, ehe bereits einen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 428,40 | -0,19 % | Vertex Pharmaceuticals Inc. Profit Climbs In Q2 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced earnings for its second quarter that Increases, from the same period last yearThe company's earnings came in... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,218 | 0,00 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 02.09.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 02.09.2026 in Berlin... ► Artikel lesen | |
| CRONOS GROUP | 2,646 | -1,19 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| DIGICANN VENTURES | 0,012 | +118,18 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,864 | +1,77 % | Organigram Global Inc: Organigram Global to release fiscal Q3 results Aug. 11 | ||
| GREEN THUMB INDUSTRIES | 5,870 | -1,68 % | Green Thumb Industries Reports Second Quarter 2026 Results | CHICAGO and VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 48,200 | -1,33 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| NOVERIS HEALTH SCIENCES | 0,292 | -9,88 % | Noveris Health Sciences Inc.: Noveris Health Sciences Inc. Unaware of Any Material Change | Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 16,940 | 0,00 % | Santhera Pharmaceuticals Holding AG: Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus | Pratteln, Switzerland, July 13, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 66,00 | -0,15 % | Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | Two global registrational Phase 3 trials initiated in ZENITH AD program
Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed... ► Artikel lesen |